Hobart Private Capital’s Bristol-Myers Squibb BMY Stock Holding History

Hobart Private Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,012	Closed	-$652K	–	52
2021 Q3	$652K	Sell	11,012 -530	-5%	-$34.9K	0.26%	54
2021 Q2	$771K	Sell	11,542 -2,236	-16%	-$146K	0.32%	40
2021 Q1	$870K	Sell	13,778 -1,480	-10%	-$92.1K	0.36%	32
2020 Q4	$946K	Sell	15,258 -369	-2%	-$22.7K	0.41%	30
2020 Q3	$942K	Buy	15,627 +13	+0.1%	+$782	0.49%	32
2020 Q2	$918K	Buy	15,614 +5,060	+48%	+$303K	0.52%	45
2020 Q1	$588K	Buy	10,554 +899	+9%	+$54.9K	0.4%	62
2019 Q4	$620K	Buy	9,655 +969	+11%	+$55.5K	0.38%	62
2019 Q3	$440K	Buy	8,686 +387	+5%	+$18.2K	0.3%	76
2019 Q2	$376K	Buy	8,299 +905	+12%	+$42.2K	0.26%	85
2019 Q1	$353K	Sell	7,394 -3,173	-30%	-$158K	0.27%	98
2018 Q4	$549K	Buy	10,567 +4,206	+66%	+$226K	0.47%	62
2018 Q3	$395K	Buy	+6,361	New	+$377K	0.3%	89

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hobart Private Capital's BMY Position: Q4 2021 in Review

Hobart Private Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2021, closing a stake of 11,012 shares — an estimated $652K sold.

Hobart Private Capital first reported a position in BMY in Q3 2018 and held it in 13 quarters. The position peaked at $946K in Q4 2020. 2,444 funds tracked by Wall St. Rank hold BMY as of Q4 2021.

Hobart Private Capital reported no remaining Bristol-Myers Squibb position as of Q4 2021 after selling out during the quarter.
Hobart Private Capital sold 11,012 Bristol-Myers Squibb shares in Q4 2021, an estimated $652K.
Hobart Private Capital first reported a position in Bristol-Myers Squibb in Q3 2018 and held it in 13 quarters.
Hobart Private Capital's Bristol-Myers Squibb position peaked at $946K in Q4 2020.
2,444 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2021.

Based on Hobart Private Capital's 13F filing for Q4 2021, filed 11 Mar 2024.